Fluoropyrimidine-Associated Cardiotoxicity: Coronary Vasospasm, Rechallenge Strategies, and Vasodilator Prophylaxis

Fluoropyrimidines, principally 5-fluorouracil (5-FU) and capecitabine, remain foundational agents in the treatment of gastrointestinal, breast, and head and neck malignancies, but they are also among the most clinically important non-anthracycline causes of cancer therapy-related cardiovascular toxicity. Clinical manifestations range from asymptomatic electrocardiographic abnormalities and biomarker elevation to angina, coronary vasospasm, myocardial infarction, arrhythmias, heart failure, Takotsubo syndrome, and sudden cardiac death. Although coronary vasospasm remains the most recognized mechanism, contemporary evidence supports a multifactorial pathophysiology involving endothelial dysfunction, oxidative stress, direct myocardial injury, mitochondrial dysfunction, thrombosis, and microvascular dysfunction. The reported incidence varies widely because of differences in definitions, surveillance intensity, cancer populations, and fluoropyrimidine schedules. Management begins with immediate discontinuation of fluoropyrimidine and evaluation for acute coronary syndrome or other cardiac emergencies. A major unresolved question is whether fluoropyrimidine therapy can be safely resumed after cardiotoxicity. Older reports suggested high recurrence rates with rechallenge, whereas more recent cardio-oncology-guided series suggest that selected patients may successfully continue treatment using vasodilator prophylaxis, regimen modification, and close monitoring. This narrative review summarizes the epidemiology, mechanisms, clinical manifestations, diagnosis, acute management, rechallenge strategies, and alternatives to fluoropyrimidines when re-exposure is unsafe.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-20
DOI
https://doi.org/10.3390/biomedicines14112695
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fluoropyrimidine-Associated Cardiotoxicity: Coronary Vasospasm, Rechallenge Strategies, and Vasodilator Prophylaxis

Supriya Peshin, Deepthi Devagudi, Sakshi Singal, Ehab Takrori et al.
2 links
Biomedicines
Chemotherapy-induced cardiotoxicity and mitigation
article

Fluoropyrimidine-Associated Cardiotoxicity: Coronary Vasospasm, Rechallenge Strategies, and Vasodilator Prophylaxis

Supriya Peshin, Deepthi Devagudi, Sakshi Singal, Ehab Takrori, Lalith Vardhan Namburu, Alanood A. AlQerainees, Sanchita Kanakannavar, Afnan H. AlSayed
article en

Abstract

Fluoropyrimidines, principally 5-fluorouracil (5-FU) and capecitabine, remain foundational agents in the treatment of gastrointestinal, breast, and head and neck malignancies, but they are also among the most clinically important non-anthracycline causes of cancer therapy-related cardiovascular toxicity. Clinical manifestations range from asymptomatic electrocardiographic abnormalities and biomarker elevation to angina, coronary vasospasm, myocardial infarction, arrhythmias, heart failure, Takotsubo syndrome, and sudden cardiac death. Although coronary vasospasm remains the most recognized mechanism, contemporary evidence supports a multifactorial pathophysiology involving endothelial dysfunction, oxidative stress, direct myocardial injury, mitochondrial dysfunction, thrombosis, and microvascular dysfunction. The reported incidence varies widely because of differences in definitions, surveillance intensity, cancer populations, and fluoropyrimidine schedules. Management begins with immediate discontinuation of fluoropyrimidine and evaluation for acute coronary syndrome or other cardiac emergencies. A major unresolved question is whether fluoropyrimidine therapy can be safely resumed after cardiotoxicity. Older reports suggested high recurrence rates with rechallenge, whereas more recent cardio-oncology-guided series suggest that selected patients may successfully continue treatment using vasodilator prophylaxis, regimen modification, and close monitoring. This narrative review summarizes the epidemiology, mechanisms, clinical manifestations, diagnosis, acute management, rechallenge strategies, and alternatives to fluoropyrimidines when re-exposure is unsafe.

BiomedicinesVol. 14(11)
University of Central Florida (US), East Tennessee State University (US), Alfaisal University (SA), Norton Community Hospital (US), University of Arkansas for Medical Sciences (US)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon